May 17 2005
Clinical trials on a new vaccine against smoking has given hope to those trying to quit. The vaccine could also prevent cigarette addiction.
Results in the first large human trial have revealed that after being injected with the vaccine, some smokers were able to kick the habit immediately. Tests on more than 340 smokers showed 57 per cent of those injected with the highest dose of the vaccine quit.
Of smokers who received low-dose vaccine levels, 32 per cent were able to butt out, and of those injected with a placebo, 31 per cent stopped smoking.
By combining nicotine with antibodies in the bloodstream, the drug blocks nicotine from entering the brain and shuts down the body's addiction to tobacco.
Swiss company Cytos Biotechnology released the findings of the trial at the American Society of Clinical Oncology's annual meeting in Florida. Cytos plans more human trials in the US and Europe.
Prof Jacques Cornuz says the results are exciting, and the data clearly suggests that antibodies against nicotine are effective in helping people quit smoking. He believes that the vaccine approach has the potential to dramatically alter the way smoking addiction is treated in the future.
Vaccine dosages and the number of injections could be increased to ensure nicotine does not enter the brain.
If the vaccine is approved by health authorities worldwide, it could be on the market by 2010.
But Quit Victoria's executive director Todd Harper is sceptical, and says there is not a miracle cure on the horizon, and even if this drug were to be successful, it will be many years down the track before it is available to the public.
Harper advises that people wanting to quit use will-power and utilise the Quit Line.
Two other companies -- the British-based Xenova and an American company called Nabi Biopharmaceuticals, are also working on a nicotine vaccine.